Dr. Reddy’s Announces the Launch of Decitabine for Injection

Dr. Reddy’s Announces the Launch of Decitabine for Injection

Hyderabad, July 12 (INN): Dr. Reddy’s Laboratories announced today that it has launched Decitabine for Injection (50mg) a therapeutic equivalent generic version of Dacogen (Decitabine for Injection) in the US market on July 11, 2013, following the approval by the United States Food & Drug Administration (USFDA) of Dr. Reddy’s ANDA for Decitabine for Injection.

The Dacogen brand has U.S. sales of approximately $260 Million MAT for the most recent twelve months ending in July 2013 according to IMS Health.

Dr. Reddy’s Decitabine for Injection 50 mg is available as a single dose vial.


Comments are closed.